Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 127

1.

Homozygous carriers of the G allele of rs4664447 of the glucagon gene (GCG) are characterised by decreased fasting and stimulated levels of insulin, glucagon and glucagon-like peptide (GLP)-1.

Torekov SS, Ma L, Grarup N, Hartmann B, Hainerová IA, Kielgast U, Kissow H, Rosenkilde M; GIANT Consortium, Lebl J, Witte DR, Jørgensen T, Sandbaek A, Lauritzen T, Madsen OD, Wang J, Linneberg A, Madsbad S, Holst JJ, Hansen T, Pedersen O.

Diabetologia. 2011 Nov;54(11):2820-31. doi: 10.1007/s00125-011-2265-7. Epub 2011 Aug 7.

PMID:
21822931
2.

Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits.

Gjesing AP, Ekstrøm CT, Eiberg H, Urhammer SA, Holst JJ, Pedersen O, Hansen T.

Diabetologia. 2012 May;55(5):1338-45. doi: 10.1007/s00125-012-2484-6. Epub 2012 Feb 15.

PMID:
22349073
3.

Plasma level of glucagon-like peptide 1 in obese Egyptians with normal and impaired glucose tolerance.

Hussein MS, Abushady MM, Refaat S, Ibrahim R.

Arch Med Res. 2014 Jan;45(1):58-62. doi: 10.1016/j.arcmed.2013.10.012. Epub 2013 Dec 7.

PMID:
24321596
5.

Altered Plasma Levels of Glucagon, GLP-1 and Glicentin During OGTT in Adolescents With Obesity and Type 2 Diabetes.

Manell H, Staaf J, Manukyan L, Kristinsson H, Cen J, Stenlid R, Ciba I, Forslund A, Bergsten P.

J Clin Endocrinol Metab. 2016 Mar;101(3):1181-9. doi: 10.1210/jc.2015-3885. Epub 2016 Jan 8.

PMID:
26745255
6.

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC.

Diabetes. 1996 Nov;45(11):1524-30.

PMID:
8866556
7.
8.

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA.

Diabetes Care. 1996 Jun;19(6):580-6.

PMID:
8725855
9.

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B.

Diabetologia. 1996 Dec;39(12):1546-53.

PMID:
8960841
10.
11.

Role of rs6923761 gene variant in glucagon-like peptide 1 receptor in basal GLP-1 levels, cardiovascular risk factor and serum adipokine levels in naïve type 2 diabetic patients.

de Luis DA, Aller R, Izaola O, Bachiller R.

J Endocrinol Invest. 2015 Feb;38(2):143-7. doi: 10.1007/s40618-014-0161-y. Epub 2014 Sep 9.

PMID:
25200998
12.

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.

Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agersø H, Veldhuis J, Pørksen N, Schmitz O.

Diabetes. 2002 Feb;51(2):424-9.

13.

Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.

Ahrén B, Larsson H, Holst JJ.

J Clin Endocrinol Metab. 1997 Feb;82(2):473-8.

PMID:
9024239
14.

Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes.

Mannucci E, Tesi F, Bardini G, Ognibene A, Petracca MG, Ciani S, Pezzatini A, Brogi M, Dicembrini I, Cremasco F, Messeri G, Rotella CM.

Diabetes Nutr Metab. 2004 Dec;17(6):336-42.

PMID:
15887627
15.

Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms.

Schäfer SA, Tschritter O, Machicao F, Thamer C, Stefan N, Gallwitz B, Holst JJ, Dekker JM, 't Hart LM, Nijpels G, van Haeften TW, Häring HU, Fritsche A.

Diabetologia. 2007 Dec;50(12):2443-50. Epub 2007 Jul 28. Erratum in: Diabetologia. 2009 Mar;52(3):557. Dosage error in article text. Diabetologia. 2008 Jan;51(1):208. t' Hart, L M [corrected to 't Hart, L M].

16.

Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.

Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W.

Diabet Med. 1998 Nov;15(11):937-45.

PMID:
9827848
17.

Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial.

Kuwata H, Iwasaki M, Shimizu S, Minami K, Maeda H, Seino S, Nakada K, Nosaka C, Murotani K, Kurose T, Seino Y, Yabe D.

Diabetologia. 2016 Mar;59(3):453-61. doi: 10.1007/s00125-015-3841-z. Epub 2015 Dec 24.

18.

Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.

Cuthbertson J, Patterson S, O'Harte FP, Bell PM.

Metabolism. 2011 Jan;60(1):52-6. doi: 10.1016/j.metabol.2010.01.001. Epub 2010 Feb 11.

PMID:
20152998
20.

Supplemental Content

Support Center